title: Ischemia-modified albümin and malondialdehyde levels in patients with overt and subclinical hyperthyroidism: effects of treatment on oxidative stress.
abstract: The main purpose of this study was to evaluate the levels of ischemia-modified albumin (IMA) and malondialdehyde (MDA) in patients with OHyper and SHyper, to assess the effects of antithyroid drug (ATD) therapy on the oxidative stress (OS) parameters. Forty-five untreated patients with overt hyperthyroidism (OHyper), 20 untreated patients with subclinical hyperthyroidism (SHyper) and 30 age-and sex-matched healthy controls were prospectively included in the study. Biochemical and hormonal parameters were evaluated in all patients before and after treatment. Compared with the control subjects, the levels of MDA, glucose and TG were significantly increased in patients with SHyper (p<0.05), whereas LDL-C levels were significantly decreased (p<0.01). Patients with OHyper showed significantly elevated MDA and glucose levels (p<0.001) and significantly decreased LDL-C and HDL-C levels compared with the controls (p<0.01). In patients with Graves' disease, serum TSH levels were inversely correlated with plasma MDA levels (r: -0.42, p<0.05). Plasma MDA levels significantly decreased and levels of TC, LDL-C and HDL-C significantly increased in the groups of OHyper and SHyper after treatment. Serum IMA levels did not significantly change at baseline and with the therapy in all subjects. In conclusion, increased MDA levels in both patient groups represent increased lipid peroxidation which might play an important role in the pathogenesis of the atherosclerosis in these patients. Increased oxidative stress in patients with SHyper and OHyper could be improved by ATD therapy. Also, MDA can be used as a reliable marker of OS and oxidative damage, while IMA is considered to be inappropriate.
authors.affiliation: Department of Internal Medicine, Division of Endocrinology and Metabolism, Karadeniz Technical University Faculty of Medicine, 61080 Trabzon, Turkey.
authors.forename: Cihangir
authors.initials: C
authors.lastname: Erem
authors.forename: Akile Karacin
authors.initials: AK
authors.lastname: Suleyman
authors.forename: Nadim
authors.initials: N
authors.lastname: Civan
authors.forename: Ahmet
authors.initials: A
authors.lastname: Mentese
authors.forename: İrfan
authors.initials: İ
authors.lastname: Nuhoglu
authors.forename: Aysegul
authors.initials: A
authors.lastname: Uzun
authors.forename: Halil Onder
authors.initials: HO
authors.lastname: Ersoz
authors.forename: Orhan
authors.initials: O
authors.lastname: Deger
mesh_terms: D000328:Adult; D000368:Aged; D013956:Antithyroid Agents / Q000009:adverse effects / Q000627:therapeutic use*; D058070:Asymptomatic Diseases / Q000628:therapy; D050197:Atherosclerosis / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D005260:Female; D006111:Graves Disease / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D006980:Hyperthyroidism / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D015227:Lipid Peroxidation / Q000187:drug effects*; D008297:Male; D008315:Malondialdehyde / Q000097:blood*; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D011446:Prospective Studies; D012306:Risk; D012709:Serum Albumin; D000075462:Serum Albumin, Human; D013972:Thyrotropin / Q000097:blood; D014280:Triglycerides / Q000097:blood; D014421:Turkey / Q000453:epidemiology
chemical_list: D013956:Antithyroid Agents; D015415:Biomarkers; D001786:Blood Glucose; D012709:Serum Albumin; D014280:Triglycerides; C561522:ischemia-modified albumin; D008315:Malondialdehyde; D013972:Thyrotropin; D002784:Cholesterol; D000075462:Serum Albumin, Human